GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dendreon Corp (FRA:DNR) » Definitions » Cyclically Adjusted Book per Share

Dendreon (FRA:DNR) Cyclically Adjusted Book per Share : €0.00 (As of Sep. 2014)


View and export this data going back to . Start your Free Trial

What is Dendreon Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Dendreon's adjusted book value per share for the three months ended in Sep. 2014 was €-1.565. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.00 for the trailing ten years ended in Sep. 2014.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-05-17), Dendreon's current stock price is €0.13. Dendreon's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2014 was €0.00. Dendreon's Cyclically Adjusted PB Ratio of today is .


Dendreon Cyclically Adjusted Book per Share Historical Data

The historical data trend for Dendreon's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dendreon Cyclically Adjusted Book per Share Chart

Dendreon Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Dendreon Quarterly Data
Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Mar15
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Dendreon's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Dendreon's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dendreon's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dendreon's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Dendreon's Cyclically Adjusted PB Ratio falls into.



Dendreon Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Dendreon's adjusted Book Value per Share data for the three months ended in Sep. 2014 was:

Adj_Book= Book Value per Share /CPI of Sep. 2014 (Change)*Current CPI (Sep. 2014)
=-1.565/100.4278*100.4278
=-1.565

Current CPI (Sep. 2014) = 100.4278.

Dendreon Quarterly Data

Book Value per Share CPI Adj_Book
200412 2.516 80.290 3.147
200503 2.312 81.555 2.847
200506 2.274 82.062 2.783
200509 1.985 83.876 2.377
200512 2.296 83.032 2.777
200603 1.696 84.298 2.021
200606 1.419 85.606 1.665
200609 1.128 85.606 1.323
200612 1.256 85.142 1.482
200703 0.894 86.640 1.036
200706 0.741 87.906 0.847
200709 0.560 87.964 0.639
200712 0.334 88.616 0.379
200803 0.175 90.090 0.195
200806 0.278 92.320 0.302
200809 0.103 92.307 0.112
200812 0.210 88.697 0.238
200903 0.107 89.744 0.120
200906 1.084 91.003 1.196
200909 0.719 91.120 0.792
200912 2.955 91.111 3.257
201003 2.155 91.821 2.357
201006 3.634 91.962 3.969
201009 2.892 92.162 3.151
201012 2.612 92.474 2.837
201103 2.580 94.283 2.748
201106 2.069 95.235 2.182
201109 1.500 95.727 1.574
201112 1.740 95.213 1.835
201203 1.374 96.783 1.426
201206 1.045 96.819 1.084
201209 0.291 97.633 0.299
201212 0.171 96.871 0.177
201303 -0.176 98.209 -0.180
201306 -0.482 98.518 -0.491
201309 -0.765 98.790 -0.778
201312 -1.129 98.326 -1.153
201403 -1.293 99.695 -1.303
201406 -1.378 100.560 -1.376
201409 -1.565 100.428 -1.565

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Dendreon  (FRA:DNR) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Dendreon Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Dendreon's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Dendreon (FRA:DNR) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dendreon Corp (FRA:DNR) » Definitions » Cyclically Adjusted Book per Share
Traded in Other Exchanges
N/A
Address
Dendreon Corp is a Delaware corporation. The Company is a biotechnology company focused on the discovery, development and commercialization of novel therapeutics that improve cancer treatment options for patients. Its product portfolio includes active cellular immunotherapy and small molecule product candidates to treat a range of cancers. PROVENGE(r) (sipuleucel-T), is its first commercialized product licensed by the United States Food and Drug Administration, and is a first in class autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, castrate-resistant (hormone-refractory) prostate cancer. Prostate cancer is the most common non-skin cancer among men in the United States, with over one million men currently diagnosed with the disease, and the second cause of cancer deaths in men in the United States. The Company owns worldwide rights for PROVENGE. The Other potential product candidates we have under development include our investigational active cellular immunotherapy, DN24-02, which potentially may be used for the treatment of patients with bladder, breast, ovarian and other solid tumors expressing HER2/neu. In addition, the Company has developed an orally-available small molecule treatment targeting TRPM8 that could be applicable to multiple types of cancer. The Company currently depends on specialized vendor relationships that are not readily replaceable for some of the components for its active immunotherapy candidates. Products such as chemotherapeutics, androgen metabolism or androgen receptor antagonists, endothelin A receptor antagonists, antisense compounds, angiogenesis inhibitors and gene therapies for cancer are also under development by a number of companies and could potentially compete with PROVENGE and its other product candidates. The Company's competitors include major pharmaceutical companies. The Company is subject to a variety of federal, state and local regulations relating to the use, handling, storage and disposal of hazardous materials, including chemicals and radioactive and biological materials. The Company is also subject to regulation by the Occupational Safety and Health Administration ('OSHA'), and the Environmental Protection Agency ('EPA'), and to regulation under the Toxic Substances Control Act.

Dendreon (FRA:DNR) Headlines

No Headlines